Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

In contrast, after adding 20 mg/kg of monoclonal antibody against CD40 ligand to the regimen on days 0 and 2, we observed four thromboembolic complications in nine recipients. These included two ...

The researchers created an antibody that could both activate CD40 and carry cancer-specific peptides to immune cells. The ...

Background Soluble CD40 ligand (sCD40L) is a powerful marker of cardiovascular risk. Exercise is known to decrease cardiovascular risk, but the impact of ultra-endurance exercise on sCD40L responses ...

We propose that memory B-cell IL-10 production evolved primarily to downregulate vigorous adaptive pathogen-specific immune responses (involving combined TLR, BCR and CD40 signalling) and would ...

Not only does it activate the right type of immune cells in human blood samples ... then start clinical trials in humans. A bispecific CD40 agonistic antibody allowing for antibody-peptide ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer.

Researchers at Uppsala University and KTH Royal Institute of Technology have created an antibody that has the potential to ...

The two patients received the treatment as part of a UChicago Medicine pilot study focusing on the use of Eledon's anti CD40 ligand (CD40L) antibody tegoprubart (formerly AT-1501) as an ...

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...

Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report)’s stock price dropped 9.4% on Monday . The stock traded as low as $4.53 and last traded at $4.53. Approximately 300 shares were traded during ...